Startups
ArrowMark Partners is an employee-owned asset management firm founded in 2007. Today, ArrowMark manages $20.8 billion* in assets on behalf of a broad array of institutional clients and professional asset allocators across alternative credit and capacity-constrained equity strategies, as well as through the management of broadly syndicated and middle-market CLO Funds. Our unique approach, based on the team’s collective experience navigating market cycles, provides extensive insights across the capital structure and a skilled understanding of how to manage complex risk/reward tradeoffs through fundamental research.
*As of 9/30/2022. CRE AUM includes commercial mortgage loans that ArrowMark or its affiliate has originated and/or currently manages on behalf of insurance companies and other institutional investors.
*As of 9/30/2022. CRE AUM includes commercial mortgage loans that ArrowMark or its affiliate has originated and/or currently manages on behalf of insurance companies and other institutional investors.
Overview
Location
United States, Colorado, Denver
Employees
51-200
Founded date
2007
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 2, 2026 | Dren Bio Announces $350 Million Financing | SAN CARLOS, CA, Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics, announced the closing of an oversubscribed $350 million private financing. >> Click here for more fundi... |
| Oct 30, 2026 | Dren Bio Raises $350 Million To Advance Dibotatug And Broader Therapeutics Pipeline | Dren Bio has closed an oversubscribed $350 million private financing to advance its lead antibody therapy dibotatug toward regulatory submission and commercialization while expanding its broader oncology and autoimmune pipeline. The financi... |
| Mar 4, 2026 | Poplar Therapeutics Raises $45M in Series A Extension Funding | Poplar Therapeutics, a Cambridge, MA-based clinical-stage immunology company, raised $45M in Series A extension funding. The round was led by Janus Henderson Investors, with participation from RA Capital, SR One, Vida Ventures and affiliate... |
| Mar 3, 2026 | Poplar Therapeutics: $45 Million Series A Extension Raised By Immunology Company To Advance Anti-IgE Therapy PHB-050 | Poplar Therapeutics, a clinical-stage immunology company developing a new class of anti-IgE therapy for food allergy and other atopic conditions, has closed a $45 million Series A extension, bringing its total Series A financing to $95 mill... |
| Feb 7, 2026 | Skyryse: $300+ Million Series C Raised At $1.15 Billion Valuation For Aviation Automation | Skyryse, an aviation automation company focused on simplified flight controls, said it raised more than $300 million in a Series C round, valuing the business at more than $1.15 billion. The company said it has now raised more than $605 mil... |
| Feb 27, 2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| Feb 20, 2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mis... |
| Feb 15, 2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know: – Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| May 25, 2023 | ArrowMark Partners’ Closes Fourth Fund Vintage Dedicated to Regulatory Capital Relief Investments with $1.1 Billion in Commitments |
Show more
Reviews 0
FAQ about ArrowMark Partners
When was ArrowMark Partners founded?
ArrowMark Partners was founded in 2007.
What has the press written about ArrowMark Partners?
Parsers VC has collected 15 articles mentioning ArrowMark Partners, among them “Dren Bio Announces $350 Million Financing” (Nov 2, 2026) and “Dren Bio Raises $350 Million To Advance Dibotatug And Broader Therapeutics Pipeline” (Oct 30, 2026).
Is ArrowMark Partners still active?
Yes, ArrowMark Partners is active; its latest activity on Parsers VC dates from Nov 2, 2026.